Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Cancers·2026
Same author

Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma.

Journal of cancer research and clinical oncology·2025
Same author

Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion.

Journal of vascular and interventional radiology : JVIR·2025
Same author

Percutaneous Hepatic Perfusion Melphalan Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in a Patient with Metastatic Uveal Melanoma.

Case reports in oncology·2025
Same author

Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.

The oncologist·2025
Same author

Proceedings of the seventh annual Women in Melanoma Conference.

Therapeutic advances in medical oncology·2025

Related Experiment Video

Updated: Feb 13, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K

Melanoma Immunotherapy in the Elderly.

Marlana Orloff1

  • 1Department of Medical Oncology, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA, 19107, USA. Marlana.Orloff@jefferson.edu.

Current Oncology Reports
|March 4, 2018
PubMed
Summary

Immunotherapy, including immune checkpoint inhibitors, is effective for elderly melanoma patients. Personalizing treatment is key due to age-related immune system changes and side effect management.

Keywords:
Anti-CTLA-4Anti-PD1Checkpoint inhibitorsElderlyGeriatricImmunotherapyMelanoma

More Related Videos

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

10.3K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Related Experiment Videos

Last Updated: Feb 13, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

10.3K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Cutaneous melanoma incidence is increasing in the elderly population.
  • Immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) show promise for melanoma.
  • Efficacy and tolerability data exist for these agents across age groups, including those over 75.

Purpose of the Study:

  • To summarize clinical experience with immunotherapy in elderly melanoma patients.
  • To introduce personalized treatment approaches for older adults.
  • To consider age-specific factors like immune system aging and side effect management.

Main Methods:

  • Review of clinical trial data and experience with immune checkpoint inhibitors.
  • Analysis of efficacy and tolerability in elderly melanoma patients.
  • Exploration of personalized strategies for optimizing treatment in older individuals.

Main Results:

  • Immunotherapy demonstrates efficacy and tolerability in elderly patients with melanoma.
  • A one-size-fits-all approach to immunotherapy may not be optimal for older adults.
  • Personalization is increasingly recognized as important for this demographic.

Conclusions:

  • Immunotherapy is a valuable treatment for elderly melanoma patients.
  • Personalized approaches are needed to optimize efficacy and manage side effects in older individuals.
  • Understanding the aging immune system is crucial for tailoring melanoma treatment.